Prism Medico and Pharmacy Sets 5 November Q2 FY27 Results

Prism Medico and Pharmacy Ltd. is scheduled to announce its unaudited standalone Q2 FY27 results for the quarter ended 30 September 2026 on 5 November 2026, following a Q1 FY27 net loss of ₹0.0583 crore and zero revenue from operations.

When will Prism Medico and Pharmacy report Q2 FY27 results?

Prism Medico and Pharmacy will report its Q2 FY27 financial results on 5 November 2026. The company has scheduled a board meeting to consider and approve unaudited standalone results for the quarter ended 30 September 2026. The disclosure identifies the proposed result announcement as a board-meeting item.

The date is significant because it will provide the next reported operating update after the June 2026 quarter. The available information states that Prism Medico and Pharmacy recorded zero revenue from operations in Q1 FY27 and a net loss of ₹0.0583 crore, or ₹5.83 lakh. The Q2 filing is therefore expected to show whether the company recorded any operating revenue during the September quarter.

The company has also made a separate compliance disclosure under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30 September 2026. That filing relates to depository-related confirmation procedures and is separate from the pending financial-results announcement.

What did Prism Medico and Pharmacy report in the latest quarter?

Prism Medico and Pharmacy reported zero revenue from operations and a net loss of ₹0.0583 crore for Q1 FY27, according to the available company-results update. The board considered and approved the unaudited standalone financial results for the quarter ended 30 June 2026 along with the auditors' limited review report.

The latest reported quarter followed audited standalone results for the quarter and financial year ended 31 March 2026. The source does not provide the full Q1 FY27 profit-and-loss statement beyond zero revenue from operations and the ₹5.83 lakh loss. As a result, details such as expenses, finance costs, exceptional items and cash flows are not available in the supplied data.

Earlier half-yearly figures show that performance has varied sharply between reporting periods. For the half year ended March 2026, net sales turnover was reported at ₹0.35 crore, operating profit at a loss of ₹0.14 crore, and reported profit after tax at a loss of ₹0.25 crore. The prior September 2025 half year showed net sales turnover of ₹2.09 crore and reported PAT of ₹0.57 crore.

How have Prism Medico and Pharmacy's earlier results changed?

Prism Medico and Pharmacy's available half-yearly data shows a decline in turnover and a move from profit to loss between September 2025 and March 2026. Net sales turnover fell from ₹2.09 crore in the half year ended September 2025 to ₹0.35 crore in the half year ended March 2026.

Operating performance also changed over that period. Operating profit was reported at ₹0.55 crore in September 2025, while the March 2026 period recorded an operating loss of ₹0.14 crore. EBITDA moved from a profit of ₹0.57 crore to a loss of ₹0.13 crore, while EBIT shifted from a profit of ₹0.57 crore to a loss of ₹0.14 crore.

The reported PAT figures followed the same direction. Prism Medico and Pharmacy recorded reported PAT of ₹0.57 crore for the September 2025 half year, compared with a loss of ₹0.25 crore for the March 2026 half year. The Q1 FY27 update, which cited zero revenue and a ₹0.0583 crore loss, adds a further data point for investors assessing recent operations.

Historical annual figures in the supplied data show much larger revenue in earlier years. Total income was ₹54.72 crore in the year ended March 2019, compared with ₹22.84 crore in March 2018 and ₹5.35 crore in March 2017. These figures are historical and should not be treated as a guide to current operating scale.

Why do the Q2 FY27 results matter for investors?

Prism Medico and Pharmacy's Q2 FY27 results matter because the filing will provide the first reported update after a quarter with zero revenue from operations. Investors will be able to compare the September-quarter revenue, profitability and expenses with the Q1 FY27 disclosure and with the half-yearly figures reported through March 2026.

The result will also clarify the company's position after a period of substantial movement in reported sales and profitability. The supplied data identifies Prism Medico and Pharmacy as engaged in the sale of pharmaceutical products in India, while another company-profile entry describes wholesaling and retailing of straw, fodder and other animal or poultry feed. The pending financial statement and accompanying disclosures will be the relevant source for assessing the company's current reported operations.

No share-price movement, analyst estimate, management guidance or market response is included in the source material. There is also no disclosed forecast for Q2 FY27 revenue or profit. Therefore, the available facts support monitoring the announced financial results rather than drawing conclusions about future performance before the filing is released.

The company was incorporated in 1985 and is based in Sirmaur, India, according to the supplied company information. Its recent disclosure record includes results announcements for the quarter ended June 2026, the quarter and full year ended March 2026, and earlier quarterly periods. The 5 November announcement continues that reporting sequence.

Conclusion

Prism Medico and Pharmacy is due to release Q2 FY27 standalone results on 5 November 2026 after reporting zero revenue from operations and a ₹0.0583 crore net loss in Q1 FY27. Earlier half-yearly data also shows turnover falling to ₹0.35 crore and reported PAT moving to a ₹0.25 crore loss in the half year ended March 2026.

Investors should watch for the reported September-quarter revenue, operating costs, EBIT and PAT, as well as any notes accompanying the unaudited standalone results. The scheduled board meeting and the quarter ended 30 September 2026 are the next disclosed milestones in the available information.